The Hong Kong team was led by Counsel Vincent Chan.

YHLO Biotech is a leading company of immunoassay solutions in China, specialised in developing, manufacturing and distributing in-vitro diagnostic instruments and reagents for diagnosis of autoimmune diseases, reproductive health, infectious diseases and others. It was founded in 2008 and is headquartered in Shenzhen China.

Vincent commented “As a leading specialist in Hong Kong for offshore initial public offerings work, this deal further demonstrates our expertise and capability in helping clients with their listings in Asia.”

Our Hong Kong Capital Markets team is highly regarded for their extensive expertise in supporting offshore companies with IPOs, introductions, placements and listings of both equity and debt securities on the Hong Kong, US, Singapore and many other internationally recognised stock exchanges.

Share
Twitter LinkedIn Email Save as PDF
More Deals
6 Jul 2021 | Deals

Appleby’s Hong Kong office acts as Cayman and BVI counsel to Datang Group Holdings Limited on its issuance of USD300 million 12.50% senior notes due 2022

It was second time the Appleby team being instructed by Datang after advising on its HKD1.48 billion...

Contributors: Kaile Yang
24 May 2021 | Deals

Appleby advises Ascendent Capital Partners on the offshore aspects of multiple transactions

Appleby advises Ascendent Capital Partners on the offshore aspects of multiple transactions.